TECregen has appointed Dr Klaas P Zuideveld as CEO. Zuideveld has over two decades of experience in the pharmaceutical and biotechnology sectors, with areas of expertise including translational ...
BASEL, Switzerland, Jan. 29, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D., as Chief Executive ...
Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group ...
Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb has developed a ...
TECregen, a biotechnology company pioneering thymus rejuvenation, has announced the appointment of Dr Klaas Zuideveld as Chief Executive Officer. Klaas will lead TECregen’s strategy and execution as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results